PHAT
Phathom Pharmaceuticals Stock Analysis
AI Rating
- Quality0/10
- Growth↑ 7/10
- Value↓ 2/10
PHAT Growth
- Revenue Y/Y↑ 121.20%
- EPS Y/Y↑ 59.54%
- FCF Y/Y↑ 65.43%
PHAT Profitability
- Gross margin ↑ 84.90%
- EPS margin↓ -76.80%
- ROIC 5Y↓ -51.38%
PHAT Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 3.4
- Interest coverage↓ -1.4
Phathom Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.